MA32012B1 - Octahydroquinolizines destinees au traitement du diabete - Google Patents

Octahydroquinolizines destinees au traitement du diabete

Info

Publication number
MA32012B1
MA32012B1 MA33011A MA33011A MA32012B1 MA 32012 B1 MA32012 B1 MA 32012B1 MA 33011 A MA33011 A MA 33011A MA 33011 A MA33011 A MA 33011A MA 32012 B1 MA32012 B1 MA 32012B1
Authority
MA
Morocco
Prior art keywords
treatment
prevention
obesity
diabetes
compounds
Prior art date
Application number
MA33011A
Other languages
Arabic (ar)
English (en)
Inventor
Klaus Frobel
Clemens Fürnsinn
Immanuel Adorjan
Leonhardt Bauer
Original Assignee
55 Pharma Drug Discovery & Dev Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07450235A external-priority patent/EP2072515B1/fr
Application filed by 55 Pharma Drug Discovery & Dev Ag filed Critical 55 Pharma Drug Discovery & Dev Ag
Publication of MA32012B1 publication Critical patent/MA32012B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne de nouvelles octahydroquinolizines utilisées dans le traitement ou la prévention du diabetes mellitus et de ses complications, dans le traitement ou la prévention de l'hyperlipidémie, dans le traitement de la dyslipidémie diabétique, dans le traitement ou la prévention du syndrome métabolique, dans le traitement de maladies liées à un dysfonctionnement métabolique, et dans le traitement de l'obésité ou de maladies liées à l'obésité. L'invention se rapporte aussi à des compositions pharmaceutiques et à des trousses comprenant lesdits composés, seuls ou combinés à d'autres médicaments ou composés, qui ont pour objet d'offrir un traitement ou une prévention améliorés des maladies et syndromes précités chez des humains ou des animaux.
MA33011A 2007-12-19 2010-07-14 Octahydroquinolizines destinees au traitement du diabete MA32012B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07450235A EP2072515B1 (fr) 2007-12-19 2007-12-19 Quinazolidines substituées pour traitement antidiabétique
AT13152008 2008-08-25
PCT/AT2008/000458 WO2009076693A1 (fr) 2007-12-19 2008-12-17 Octahydroquinolizines destinées au traitement du diabète

Publications (1)

Publication Number Publication Date
MA32012B1 true MA32012B1 (fr) 2011-01-03

Family

ID=40430049

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33011A MA32012B1 (fr) 2007-12-19 2010-07-14 Octahydroquinolizines destinees au traitement du diabete

Country Status (16)

Country Link
US (1) US20110003808A1 (fr)
EP (1) EP2222673A1 (fr)
JP (1) JP2011506485A (fr)
KR (1) KR20100107469A (fr)
CN (1) CN101918402A (fr)
AP (1) AP2010005317A0 (fr)
AU (1) AU2008338287B2 (fr)
BR (1) BRPI0821160A2 (fr)
CA (1) CA2710006A1 (fr)
EA (1) EA201070750A1 (fr)
IL (1) IL205752A0 (fr)
MA (1) MA32012B1 (fr)
MX (1) MX2010006173A (fr)
NZ (1) NZ585307A (fr)
WO (1) WO2009076693A1 (fr)
ZA (1) ZA201003316B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500807A (ja) * 2008-08-25 2012-01-12 ５５ ファルマ ドラッグ ディスカバリー アンド ディベロップメント アーゲー 抗糖尿病治療用オクタヒドロキノリジン
JP6520440B2 (ja) * 2014-06-16 2019-05-29 有限会社バイオシステムコンサルティング 新規化合物
CN110746282A (zh) * 2019-11-04 2020-02-04 天津市安凯特科技发展有限公司 一种4-氯-2-丁酮的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795318B (en) * 1978-10-13 1980-09-24 Hoffmann La Roche Phenyl quinolizidines
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists

Also Published As

Publication number Publication date
KR20100107469A (ko) 2010-10-05
NZ585307A (en) 2011-11-25
US20110003808A1 (en) 2011-01-06
AU2008338287A1 (en) 2009-06-25
MX2010006173A (es) 2010-09-30
CN101918402A (zh) 2010-12-15
BRPI0821160A2 (pt) 2015-06-16
IL205752A0 (en) 2010-11-30
JP2011506485A (ja) 2011-03-03
AP2010005317A0 (en) 2010-08-31
CA2710006A1 (fr) 2009-06-25
WO2009076693A1 (fr) 2009-06-25
AU2008338287B2 (en) 2012-06-07
EP2222673A1 (fr) 2010-09-01
EA201070750A1 (ru) 2010-12-30
ZA201003316B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA30875B1 (fr) Therapie de combinaison avec des inhibiteurs de sglt-2 et leurs compositions pharmaceutiques
EP2214480A4 (fr) Procédés de traitement d'une stéatohépatite non alcoolique au moyen de produits à base de cystéamine
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA46219B1 (fr) Composés de co-agonistes du glucagon et du glp-1
MA41083A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA33743B1 (fr) Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur
JO3813B1 (ar) أحماض دهنية جديدة واستخدامها بالاقتران مع جزيئات حيوية
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
CL2007003262A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
MA30337B1 (fr) Anticorps
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
EP1848432A4 (fr) Composition pharmaceutique pour le traitement ou la prevention de pathologies comprenant l'obesite, le diabete, les syndromes metaboliques, les maladies neurodegeneratives, et les maladies liees a une dysfonction mitochondriale
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
EP1962601A4 (fr) Amino-piperidines fusionnees en tant qu'inhibiteurs de la dipeptidyl peptidase-4 pour le traitement ou la prevention du diabete
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
MA33299B1 (fr) Nouvelle formulation de naproxène
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
EP2296665A4 (fr) Composition pharmaceutique destinée au traitement de l'éjaculation précoce
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі